Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
about
Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health TreatmentThe Research Domain Criteria (RDoC) Project and Studies of Risk and Resilience in Maltreated ChildrenPharmacotherapy for anxiety disorders in children and adolescentsDysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and contextual fear conditioning.Physical Activity Modulates Common Neuroplasticity Substrates in Major Depressive and Bipolar Disorder.Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia.A novel treatment for tinnitus and tinnitus-related cognitive difficulties using computer-based cognitive training and D-cycloserinePsychiatric disorders: diagnosis to therapyA randomized controlled trial of cognitive remediation and d-cycloserine for individuals with bipolar disorder.The genetics of cognitive impairment in schizophrenia: a phenomic perspective.Glutamate modulators in the treatment of obsessive-compulsive disorder.Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart reviewCentral amygdala nucleus (Ce) gene expression linked to increased trait-like Ce metabolism and anxious temperament in young primates.RDoC and translational perspectives on the genetics of trauma-related psychiatric disorders.Strain differences in the effects of chronic corticosterone exposure in the hippocampusNeural mechanisms underlying heterogeneity in the presentation of anxious temperament.Enhanced antidepressant-like effects of electroacupuncture combined with citalopram in a rat model of depression.Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.Overview of glutamatergic neurotransmission in the nervous system.Modulating neural plasticity with non-invasive brain stimulation in schizophrenia.Pharmacological treatment of obsessive-compulsive disorderSerotonin dysregulation in Fragile X Syndrome: implications for treatment.Temporal Dynamics of Acute Stress-Induced Dendritic Remodeling in Medial Prefrontal Cortex and the Protective Effect of Desipramine.Vanishing clinical psychopharmacology.Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review.Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic.The association of dietary inflammatory potential with depression and mental well-being among U.S. adults.Baicalin Reverses Depressive-Like Behaviours and Regulates Apoptotic Signalling Induced by Olfactory Bulbectomy.Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.Influence of Physical Activity on Human Sensory Long-Term Potentiation.
P2860
Q26741515-6C585636-14FB-485B-AB28-C730985429FCQ26799558-BB3325A2-94E5-4FE4-A8C3-87DB8EE192D4Q26853715-81DAB79E-D63F-4746-888A-7F166210A768Q30573050-3631EBE6-9AE2-45E1-81F7-097D45DFE72EQ33655590-9DBB8008-96A6-416D-9A77-F660A2C7F703Q33847022-180ECEE0-B6F5-4355-85A3-4FB314DFE5A2Q33912531-E43D45F7-4CB4-429A-85E0-8AA13B84CF94Q33922884-909AEB3A-1075-4D4E-A1C0-62A26E1DB4C2Q34729257-EB76B283-CCEA-45B8-8C61-E0E73FE1918FQ35186661-55E758A1-5241-4C5A-B43D-B799EAB1B992Q35897264-D30180BF-D53D-46BF-B6A5-6807ED8FB3B3Q36169046-51C19C93-01C1-4456-8F00-F640CBCE3207Q36397750-2DB1BEC4-338B-4E44-A88D-BA195DB9B2DAQ36583520-2D16CAA6-24E4-495D-8C1B-FCA2AB230B14Q36653574-63BE6614-4D08-438E-ABA9-269296879C13Q36762484-1FAAA155-1349-4CCE-89C3-60495A501844Q36882888-44F3730E-2C15-423C-B545-CAC404D7E016Q36899381-E86323ED-1D05-4A1F-BCC6-163E918A2AEDQ37926162-9BC02A27-A6D7-463B-9A47-BDCEF2CA370DQ38141822-AF8D7E30-65FE-43A0-B526-63F0D8A6C8A0Q38242548-9D18F556-50E2-44E2-B39D-BC3AB178865CQ38326506-CE95BF73-C6EB-46FB-A9E0-E1B13AD73DE1Q40368537-444136DC-B1E4-4EF4-9367-E88912FC32F3Q42836394-7A1F5B38-49CB-4625-883C-8213D5C814EAQ46365588-F998B689-16A1-4E11-ADFA-F7F11411143FQ47636416-4ED832CB-69A9-4D33-B05C-B1524CBE3B0DQ47766679-301EFE6F-F66F-4ED8-AD6C-B32EBCB06714Q48068249-5BC4D71F-C7E0-4845-8F0A-3063407EC40FQ50533040-FFD2154F-7359-4BBC-9071-5F7C62A8C682Q52146711-156001C2-98D6-4CA4-A849-D600B53ACDA9
P2860
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Neuroplasticity as a target fo ...... disorders, and schizophrenia.
@ast
Neuroplasticity as a target fo ...... disorders, and schizophrenia.
@en
type
label
Neuroplasticity as a target fo ...... disorders, and schizophrenia.
@ast
Neuroplasticity as a target fo ...... disorders, and schizophrenia.
@en
prefLabel
Neuroplasticity as a target fo ...... disorders, and schizophrenia.
@ast
Neuroplasticity as a target fo ...... disorders, and schizophrenia.
@en
P2093
P2860
P921
P1433
P1476
Neuroplasticity as a target fo ...... disorders, and schizophrenia.
@en
P2093
D Cyril D'Souza
David F Tolin
Deane E Aikins
Gerard Sanacora
Graham V Williams
John H Krystal
Ralph E Hoffman
Stacy A Castner
P2860
P304
P356
10.1016/J.DRUDIS.2009.05.002
P577
2009-05-19T00:00:00Z